UNLIMITED TURBO LONG - ELI LILLY & CO | Real-time Borsa Italiana 13:02:26 03/07/2024 BST | ||
| 10.34 EUR | +4.23% |
|
| Current month | -1.59% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 10.34 | +4.23% |
| 02/07/24 | 9.92 | -7.20% |
| 01/07/24 | 10.69 | +6.05% |
| 28/06/24 | 10.08 | -1.37% |
| 27/06/24 | 10.22 | +6.02% |
Real-time Borsa Italiana
Last update July 03, 2024 at 01:02 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| P23Y25 | |
| ISIN | NLBNPIT23Y25 |
| Date issued | 12/06/2024 |
| Strike | 821.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.02 € |
|---|---|
| Lowest since issue | 5.66 € |
| Spread | 1.02 € |
| Spread % | 9.21% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
906.7
USD
Average target price
870.3
USD
Spread / Average Target
-4.02%
- Stock Market
- Certificates
- P23Y25 Certificat
